Chengdu Olymvax Biopharmaceuticals Inc. Posted 2.3 Million Yuan Net Profit in First Quarter of 2023

Chengdu Olymvax Biopharmaceuticals Inc. (成都欧林生物科技股份有限公司) (688319.SH) reported a net profit of 2.3 million yuan in the first quarter of 2023, reversing a net loss of 6.8 million yuan for the same period in the previous year.

Meanwhile, the company posted 66.9 million yuan in revenue, up 24.9% year-on-year.

At the end of the reporting period, it had 1.4 billion yuan in total assets and 509.6 million yuan in total liabilities, with a liability-to-asset ratio of 36.3%.